Back to Search
LINDA WELNIAK, MD
MD
Family Medicine Physician
NPI: 1316054372Individual
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
34897(WI)
Research & Publications (20)
Immunomodulation and pharmacological strategies in the treatment of graft-versus-host disease.
PMID 18710355·Expert Opin Pharmacother·2008
6-review
CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus.
PMID 18566369·J Immunol·2008
7-preclinical
Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation.
PMID 18539902·Blood·2008
7-preclinical
Regulatory and conventional CD4+ T cells show differential effects correlating with PD-1 and B7-H1 expression after immunotherapy.
PMID 18292520·J Immunol·2008
4-observational
The synthetic triterpenoid, CDDO, suppresses alloreactive T cell responses and reduces murine early acute graft-versus-host disease mortality.
PMID 17448911·Biol Blood Marrow Transplant·2007
7-preclinical
IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy.
PMID 17334371·Nat Med·2007
7-preclinical
Immunobiology of allogeneic hematopoietic stem cell transplantation.
PMID 17129175·Annu Rev Immunol·2007
6-review
Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression.
PMID 16709811·J Immunol·2006
7-preclinical
Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells.
PMID 16567639·Proc Natl Acad Sci U S A·2006
7-preclinical
Peyer patches are not required for acute graft-versus-host disease after myeloablative conditioning and murine allogeneic bone marrow transplantation.
PMID 16160014·Blood·2006
7-preclinical
Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity.
PMID 15961519·Blood·2005
7-preclinical
Lack of correlation between an assay used to determine early marrow allograft rejection and long-term chimerism after murine allogeneic bone marrow transplantation: effects of marrow dose.
PMID 15812390·Biol Blood Marrow Transplant·2005
7-preclinical
Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects.
PMID 15282531·Biol Blood Marrow Transplant·2004
7-preclinical
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.
PMID 15148407·Proc Natl Acad Sci U S A·2004
7-preclinical
An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease.
PMID 15003318·Exp Hematol·2004
7-preclinical
Effects of organ-specific loss of insulin-like growth factor-I production on murine hematopoiesis.
PMID 14752777·Biol Blood Marrow Transplant·2004
7-preclinical
Effects of housing on the thymic deficiency in dwarf mice and its reversal by growth hormone administration.
PMID 14597218·Clin Immunol·2003
7-preclinical
Immunologic and hematopoietic effects of recombinant human prolactin after syngeneic bone marrow transplantation in mice.
PMID 12869956·Biol Blood Marrow Transplant·2003
7-preclinical
Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses.
PMID 12594303·J Immunol·2003
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 840 RACINE STREET
JEFFERSON, WI 53549 - Phone
- (920) 674-6000
Quick Facts
- NPI
- 1316054372
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile